Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions;18F-FDG PET-TC con doppio tempo di acquisizione nella identificazione delle lesioni mammarie

Radiologia Medica

Volumn 115, Issue 2, 2010, Pages 215-224

  Caprio, M G ^a   Cangiano, A ^b   Imbriaco, M ^b   Soscia, F ^b   Di Martino, G ^c   Farina, A ^c   Avitabile, G ^b   Pace, L ^b   Forestieri, P ^c   Salvatore, M ^a,b  

^a SDN Istituto di Ricerca Diagnostica e Nucleare   (Italy)

^b Dipartimento di Scienze Biomorfologiche e Funzionali   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

18F FDG PET CT; Breast carcinoma; Dual phase acquisition; Lesion identification

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BREAST TUMOR; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MAMMOGRAPHY; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAMMOGRAPHY; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951296120     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-009-0491-6     Document Type: Article

References (22)

1. A. Jemal R. Siegel E. Ward, et al. 2007 Cancer statistics CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
2. H. Schirrmeister T. Kuhn A. Guhlmann, et al. 2001 Fluorine-18-2-deoxy-2- fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 351 358 10.1007/s002590000448 1:CAS:528:DC%2BD3MXitFeiu7o%3D 11315604
3. W.B. Eubank D.A. Mankoff 2005 Evolving role of positron emission tomography in breast cancer imaging Semin Nucl Med 35 84 99 10.1053/j. semnuclmed.2004.11.001 15765372 (Pubitemid 40568742)
4. A. Matthies M. Hicheson A. Cuchiara A. Alavi 2002 Dual time point 18F-FDG PET for the evaluation of pulmonary nodules J Nucl Med 43 871 875 12097455
5. R. Kumar V.A. Loving A. Chauhan, et al. 2005 Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET J Nucl Med 46 1819 1824 16269595
6. A. Mavi M. Urhan J.Q. Yu, et al. 2006 Dual Time point 18F-FDG-PET imaging detects breast cancers with high sensitivity and correlates well with histologic subtypes J Nucl Med 47 1440 1446 16954551
7. American College of Radiology (1995) Breast imaging reporting and data system (BI-RADS). American College of Radiology, Reston
8. Kennedy BJ (ed) (1992) Manual for the staging of cancer. Lippincott, Philadelphia
9. A. Buck H. Schirrmeister T. Kuhn, et al. 2002 FDG uptake in breast cancer correlation with biological and clinical prognostic parameters Eur J Nucl Med Imaging 29 1317 1323 10.1007/s00259-002-0880-8 1:CAS:528:DC%2BD38Xnt1Gnsr8%3D (Pubitemid 44392212)
10. V.J. Lowe J.W. Fletcher L. Gobar, et al. 1998 Prospective investigation of positron emission tomography in lung nodules J Clin Oncol 16 1075 1084 1:STN:280:DyaK1c7mslKiug%3D%3D 9508193 (Pubitemid 28108743)
11. N.A. Dewan N.C. Gupta L.S. Redepenning, et al. 1993 Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules. Potential role in evaluation and management Chest 104 997 1002 10.1378/chest.104.4.997 1:STN:280: DyaK2c%2FgvVWktw%3D%3D 8404239
12. H. Zhuang M. Pourdehnad E.S. Lambright, et al. 2001 Dual time point FDG PET imaging for differentiating malignant form inflammatory processes J Nucl Med 42 1412 1417 1:STN:280:DC%2BD3Mvptlersg%3D%3D 11535734
13. R. Hustinx R.J. Smith F. Benard, et al. 1999 Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck Eur J Nucl Med 26 1345 1348 10.1007/s002590050593 1:STN:280: DC%2BD3c%2FgvFCnsQ%3D%3D 10541835 (Pubitemid 29467031)
14. K. Koyama T. Okamura J. Kawabe, et al. 2002 The usefulness of FDG-PET images obtained 2 hours after intravenous injection in liver tumor Ann Nucl Med 16 169 176 10.1007/BF02996297 12126041
15. T. Torizuka N. Tamaki T. Inokuma, et al. 1995 In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET J Nucl Med 36 1811 1817 1:STN:280:DyaK28%2FgslKgsw%3D%3D 7562048
16. Y. Nishiyama Y. Yamamoto T. Monden, et al. 2005 Evaluation of delayed additional FDG-PET imaging in patients with pancreatic tumour Nucl Med Comm 26 895 901 10.1097/00006231-200510000-00008 (Pubitemid 41426552)
17. N. Avril C.A. Rosè M. Schelling, et al. 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 3495 3502 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
18. R. Kumar A. Chauhan H. Zhuang, et al. 2006 Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography: variations with age, breast density, and menopausal status Mol Imaging Biol 8 355 362 10.1007/s11307-006-0060-5 17053861 (Pubitemid 44741373)
19. D. Hellwig T.P. Graeter D. Ukena, et al. 2007 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense ? J Nucl Med 48 1761 1766 10.2967/jnumed.107.044362 17942814 (Pubitemid 350099319)
20. K. Murthy M. Aznar C.J. Thompson, et al. 2000 Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG J Nucl Med 41 1851 1858 1:STN:280:DC%2BD3M%2FktFOltw%3D%3D 11079494
21. L. Tafra 2007 Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons Ann Surg Oncol 14 3 13 10.1245/s10434-006-9019-7 17066235 (Pubitemid 44954265)
22. I.N. Weinberg D. Beylin V. Zavarzin, et al. 2005 Positron emission mammography: high-resolution biochemical breast imaging Technol Cancer Res Treat 4 55 60 15649088